GUFICBIO427.80

Gufic Biosciences Limited

· Pharma & Health
₹ CrorePeersRPGLIFEUNICHEMLABGUJTHEMORCHPHARMASMSPHARMAINDSWFTLABFDCIOLCPMcap ₹4,290 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity16.1711.599.669.66
Return on Assets7.885.964.784.78
Return on Capital Employed17.8814.5314.6114.61
Return on Invested Capital11.319.389.0510.02
Margins
EBITDA Margin18.0816.4316.0316.78
Operating Margin15.9713.8612.7712.77
Incremental Operating Margin-115.875.53
Pretax Margin14.3411.489.1710.12
Net Income Margin10.688.506.807.49
FCF Margin-14.905.741.461.46
Additional
Effective Tax Rate25.5326.0225.8126.04
Dvd Payout Ratio1.131.441.56
Sustainable Growth Rate15.9911.429.519.66
Incremental Operating Margin %-115.875.5335.90
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.